Journal of Nippon Medical School: Vol.71 No.1 page.002

Journal of Nippon Medical School

Select Language
in Japanese < > in English

Full Text of this Article

in English PDF (141K)

ArticleTitle Trial of Targeting Therapy Against Malignant Glioma Using Monoclonal Antibody

AuthorList Hiroshi Takahashi and Akira Teramoto

Affiliation Department of Neurosurgery, Nippon Medical School

Language EN

Volume 71

Issue 1

Year 2004

Page 2-3

Received

Accepted

Keywords

Abstract Although the conventional treatment of malignant gliomas including surgery, radiotherapy and systemic chemotherapy has advanced, their current prognosis remains poor. The reactivity of monoclonal antibodies (mAbs) with human tumor cells may allow precise localization and appropriate therapy. We have developed several mAbs against malignant gliomas, and have reported the results of the experimental studies aimed at their clinical application as targeting therapy. The initial results of employing murine mAb 425 which binds to specifically to the epidermal growth factor (EGF) receptor in glioma therapy have been excellent, but less satisfactory, possively due to the immunogenicity of the murine mAbs, and limitations of the efficacy of the unmodified antibodies. Therefore, we also investigated the accumulation and the tumor suppression effect of human mAb CLNIgG and CLNIgG-drug (DXR: doxorubicin) conjugates to the tumor. The human mAb CLNIgG, dereived from human uterine cancer lymph node cells, was found to bind strongly to human malignant glioma cells.

Correspondence to hitaka84@nms.ac.jp

ArticleTitle	Trial of Targeting Therapy Against Malignant Glioma Using Monoclonal Antibody
AuthorList	Hiroshi Takahashi and Akira Teramoto
Affiliation	Department of Neurosurgery, Nippon Medical School
Language	EN
Volume	71
Issue	1
Year	2004
Page	2-3
Received
Accepted
Keywords
Abstract	Although the conventional treatment of malignant gliomas including surgery, radiotherapy and systemic chemotherapy has advanced, their current prognosis remains poor. The reactivity of monoclonal antibodies (mAbs) with human tumor cells may allow precise localization and appropriate therapy. We have developed several mAbs against malignant gliomas, and have reported the results of the experimental studies aimed at their clinical application as targeting therapy. The initial results of employing murine mAb 425 which binds to specifically to the epidermal growth factor (EGF) receptor in glioma therapy have been excellent, but less satisfactory, possively due to the immunogenicity of the murine mAbs, and limitations of the efficacy of the unmodified antibodies. Therefore, we also investigated the accumulation and the tumor suppression effect of human mAb CLNIgG and CLNIgG-drug (DXR: doxorubicin) conjugates to the tumor. The human mAb CLNIgG, dereived from human uterine cancer lymph node cells, was found to bind strongly to human malignant glioma cells.
Correspondence to	hitaka84@nms.ac.jp